Summary
The product Injectable Dbol 25mg, manufactured by Olympian Pharmaceutical, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number 0069, was submitted by Olympian Pharmaceutical and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis detected the presence of Methandienone, with a measured concentration of 27.85 mg/ml, which is 11.4% above the labeled claim of 25 mg/ml.
The testing process began on 24 October 2024, with the sample received on 30 October 2024, and analysis completed on 1 November 2024. The results confirm that the product contains a higher concentration than stated. While an over-concentration may suggest strong potency, it also raises concerns about dosing precision and consistency across batches. Independent third-party testing is recommended to validate these findings. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Olympian Pharmaceutical
- Product Name: Injectable Dbol 25mg
- Active Ingredient: Methandienone
- Batch Number: 0069
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #51796
- Testing Ordered: 24 October 2024
- Sample Received: 30 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Olympian Pharmaceutical (Manufacturer)
- Analysis Paid For By: Olympian Pharmaceutical (Manufacturer)
Testing Results
- Specification: 25 mg/ml (as stated on the label)
- Measured Concentration: 27.85 mg/ml
- Accuracy: 111.4% (11.4% above the label claim)
Verification Details
Verification URL: https://janoshik.com/tests/51796_1V47K4R6PGVR
Evaluation of Manufacturer-Submitted Testing
This analysis confirms that Injectable Dbol 25mg contains a higher Methandienone concentration than labeled, exceeding the expected dose by 11.4%. While this suggests increased potency, it also raises concerns about dosing accuracy, as variations in concentration can affect intended results and safety. As this test was submitted and funded by Olympian Pharmaceutical, independent third-party validation is recommended to ensure batch-to-batch consistency. While Janoshik Analytical is recognized for its rigorous and transparent testing, additional external verification would enhance confidence in these findings.
Conclusion
The findings confirm that Injectable Dbol 25mg is overdosed, with a measured concentration of 27.85 mg/ml, exceeding the labeled 25 mg/ml. This deviation highlights the need for precise quality control to maintain accurate dosing across all batches. This report is provided as an educational resource to promote harm reduction and informed decision-making.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it still provides useful data when critically assessed alongside third-party or independent results. Readers are encouraged to interpret this information responsibly.
